Heat shock protein-90 inhibitor, NVP-AUY922, is effective in combination with fludarabine against chronic lymphocytic leukemia cells cultured on CD40L-stromal layer and inhibits their activated/proliferative phenotype

Leukemia and Lymphoma

Volumn 53, Issue 11, 2012, Pages 2314-2320

  Best, O Giles ^a,b   Mulligan, Stephen P ^a,b  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b CLL Australian Research Consortium   (Australia)

Author keywords

AUY922; Chronic lymphocytic leukemia; microenvironment

Indexed keywords

2FARAA; 5 (2,4 DIHYDROXY 5 ISOPROPYLPHENYL) 4 (4 MORPHOLINOMETHYLPHENYL) 3 ISOXAZOLECARBOXYLIC ACID ETHYLAMIDE; B7 ANTIGEN; CD38 ANTIGEN; CD40 ANTIGEN; CD40 LIGAND; CD69 ANTIGEN; CD71 ANTIGEN; CD86 ANTIGEN; FLUDARABINE; STAT3 PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; CELL ACTIVATION; CELL VIABILITY; CHRONIC LYMPHATIC LEUKEMIA; COCULTURE; CONCENTRATION RESPONSE; CONFERENCE PAPER; CONTROLLED STUDY; FIBROBLAST; HUMAN; IMMUNOPHENOTYPING; IN VITRO STUDY; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, CD40; APOPTOSIS; CD40 LIGAND; CELL LINE, TUMOR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; HSP90 HEAT-SHOCK PROTEINS; HUMANS; IMMUNOPHENOTYPING; ISOXAZOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MICE; PHENOTYPE; RECEPTOR TYROSINE KINASE-LIKE ORPHAN RECEPTORS; RESORCINOLS; STAT3 TRANSCRIPTION FACTOR; STROMAL CELLS; VIDARABINE;

EID: 84867170239     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2012.698278     Document Type: Conference Paper

References (25)

1. Edelmann J, Klein-Hitpass L, Carpinteiro A, et al. Bone marrow f broblasts induce expression of PI3K/NF-kappaB pathway genes and a pro-angiogenic phenotype in CLL cells. Leuk Res 2008; 32 :1565-1572.
2. Ghia P, Granziero L, Chilosi M, et al. Chronic B cell malignancies and bone marrow microenvironment. Semin Cancer Biol 2002; 12 :149-155. (Pubitemid 34680744)
3. Rosati S, Kluin PM. Chronic lymphocytic leukaemia: a review of the immuno-architecture. Curr Top Microbiol Immunol 2005;294:91-107. (Pubitemid 41508760)
4. Hazan-Halevy I, Harris D, Liu Z, et al. STAT3 is constitutively phosphorylated on serine 727 residues, binds DNA, and activates transcription in CLL cells. Blood 2010;115:2852-2863.
5. Longo PG, Laurenti L, Gobessi S, et al. The Akt/Mcl-1 pathway plays a prominent role in mediating antiapoptotic signals downstream of the B-cell receptor in chronic lymphocytic leukemia B cells. Blood 2008;111:846-855.
6. Furman RR, Asgary Z, Mascarenhas JO, et al. Modulation of NF-kappa B activity and apoptosis in chronic lymphocytic leukemia B cells. J Immunol 2000;164:2200-2206. (Pubitemid 30108780)
7. Wickremasinghe RG, Prentice AG, Steele AJ. Aberrantly activated anti-apoptotic signalling mechanisms in chronic lymphocytic leukaemia cells: clues to the identif cation of novel therapeutic targets. Br J Haematol 2011;153:545-556.
8. Burger JA. Nurture versus nature: the microenvironment in chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2011:96-103.
9. Van den Hove LE, Van Gool SW, Vandenberghe P, et al. CD40 triggering of chronic lymphocytic leukemia B cells results in ef cient alloantigen presentation and cytotoxic T lymphocyte induction by up-regulation of CD80 and CD86 costimulatory molecules. Leukemia 1997;11:572-580. (Pubitemid 27173945)
10. Cuni S, Perez-Aciego P, Perez-Chacon G, et al. A sustained activation of PI3K/NF-kappaB pathway is critical for the survival of chronic lymphocytic leukemia B cells. Leukemia 2004; 18 :1391-1400. (Pubitemid 39136749)
11. Hertlein E, Wagner AJ, Jones J, et al. 17-DMAG targets the nuclear factor-kappaB family of proteins to induce apoptosis in chronic lymphocytic leukemia: clinical implications of HSP90 inhibition. Blood 2010;116:45-53.
12. Best OG, Singh N, Forsyth C, et al. The novel Hsp-90 inhibitor SNX7081 is signif cantly more potent than 17-AAG against primary CLL cells and a range of haematological cell lines, irrespective of lesions in the TP53 pathway. Br J Haematol 2010;151:185-188.
13. Best OG, Che Y, Singh N, et al. The Hsp90 inhibitor SNX-7081 synergizes with and restores sensitivity to f udarabine in chronic lymphocytic leukemia cells with lesions in the TP53 pathway: a potential treatment strategy for f udarabine refractory disease. Leuk Lymphoma 2012 Jan 31. [Epub ahead of print]
14. Best OG, Gardiner AC, Majid A, et al. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL. Leukemia 2008;22:1456-1459. (Pubitemid 352006096)
15. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94:1840-1847. (Pubitemid 29430399)
16. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363 :105-111. (Pubitemid 38068326)
17. Buhmann R, Nolte A, Westhaus D, et al. CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates dif erent types of efector cells. Blood 1999;93:1992-2002. (Pubitemid 29128502)
18. Deaglio S, Capobianco A, Bergui L, et al. CD38 is a signaling molecule in B-cell chronic lymphocytic leukemia cells. Blood 2003; 102:2146-2155. (Pubitemid 37122392)
19. Damle RN, Ghiotto F, Valetto A, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002;99:4087-4093. (Pubitemid 35332051)
20. Ahmed-Choudhury J, Williams KT, Young LS, et al. CD40 mediated human cholangiocyte apoptosis requires JAK2 dependent activation of STAT3 in addition to activation of JNK1/2 and ERK1/2. Cell Signal 2006;18:456-468. (Pubitemid 41790366)
21. Li P, Harris D, Liu Z, et al. Stat3 activates the receptor tyrosine kinase like orphan receptor-1 gene in chronic lymphocytic leukemia cells. PLoS One 2010;5:e11859.
22. Daneshmanesh AH, Mikaelsson E, Jeddi-Tehrani M, et al. Ror1, a cell surface receptor tyrosine kinase is expressed in chronic lymphocytic leukemia and may serve as a putative target for therapy. Int J Cancer 2008;123:1190-1195.
23. Kurtova AV, Balakrishnan K, Chen R, et al. Diverse marrow stromal cells protect CLL cells from spontaneous and drug-induced apoptosis: development of a reliable and reproducible system to assess stromal cell adhesion-mediated drug resistance. Blood 2009;114:4441-4450.
24. Castro JE, Prada CE, Loria O, et al. ZAP-70 is a novel conditional heat shock protein 90 (Hsp90) client: inhibition of Hsp90 leads to ZAP-70 degradation, apoptosis, and impaired signaling in chronic lymphocytic leukemia. Blood 2005; 106 :2506-2512. (Pubitemid 41510826)
25. McCaig AM, Cosimo E, Leach MT, et al. Dasatinib inhibits B cell receptor signalling in chronic lymphocytic leukaemia but novel combination approaches are required to overcome additional pro-survival microenvironmental signals. Br J Haematol 2011; 153 :199-211.